Abstract:The human leucine-rich repeats and immunoglobulin-like domains (LRIG) gene family contains LRIG1, 2 and 3, encoding integral membrane proteins with an ectodomain, a transmembrane domain and a cytoplasmic tail. LRIG1 negatively regulates multiple receptor tyrosine kinases signaling including the epidermal growth factor receptor (EGFR) and is a proposed tumor suppressor. The soluble LRIG1 ectodomain is demonstrated to be shed naturally and inhibit the progression of glioma. However, little is known regarding the functions of LRIG2. In oligodendroglioma, LRIG2 expression is associated with poor survival, suggesting that LRIG2 might have different functions compared with LRIG1. Since soluble LRIG1 ectodomain has a similar function to the full-length LRIG1, we hypothesize that the different roles exerted by LRIG2 and LRIG1 result from the difference of their ectodomains. Here, we addressed the functions of LRIG2 and LRIG2 ectodomain in the proliferation and apoptosis of glioma and the possible underlying mechanisms. Firstly, we found that LRIG2 expression levels positively correlated with the grade of glioma. Further, we demonstrated for the first time that soluble LRIG2 ectodomain was capable of being released from glioblastoma cells and exerted a pro-proliferative effect. Overexpression of LRIG2 ectodomain promoted the proliferation and inhibited the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2. Both full-length LRIG2 and LRIG2 ectodomain were found to physically interact with EGFR, enhance the activation of EGFR and its downstream PI3 K/Akt pathway. To our knowledge, this is the first report demonstrating that soluble LRIG2 ectodomain is capable of being released from glioblastoma cells and exerts a similar role to the full-length LRIG2 in the regulation of EGFR signaling in the progression of glioblastoma. LRIG2 ectodomain, with potent pro-tumor effects, holds promise for providing a new therapeutic target for the treatment of glioblastoma.

LRIG1 regulates invasion and migration of human gliomas through SNAI2 and E-cadherin

LRIG 1-modulated invasion and metastasis of human gliomas through regulation of SNAI 2 and E-cadherin

Role of SNAI2 and E-cadherin in regulation of invasiveness and metastasis of human gliomas U251 cells by LRIG1

A Role for LRIG1 in the Regulation of Malignant Glioma Aggressiveness.

LRIG1 Dictates the Chemo-Sensitivity of Temozolomide (TMZ) in U251 Glioblastoma Cells Via Down-Regulation of EGFR/topoisomerase-2/Bcl-2

miR-19b-3p inhibits glioma progression via interacting with lncRNA HAGLR

LRIG1 Enhances Chemosensitivity by Modulating BCL-2 Expression and Receptor Tyrosine Kinase Signaling in Glioma Cells.

Long Noncoding RNA Lncherg Promotes Cell Proliferation, Migration and Invasion in Glioblastoma

Downregulation of LRIG2 expression inhibits angiogenesis of glioma via EGFR/VEGF-A pathway

LRIG 1 Enhances the Radiosensitivity of Radioresistant Human Glioblastoma U 251 Cells Via Attenuation of the EGFR / Akt Signaling Pathway

Increased Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 Expression Enhances Chemosensitivity in Glioma

Soluble Lrig2 Ectodomain Is Released From Glioblastoma Cells And Promotes The Proliferation And Inhibits The Apoptosis Of Glioblastoma Cells In Vitro And In Vivo In A Similar Manner To The Full-Length Lrig2

Lnc-Nlc1-c Inhibits Migration, Invasion and Autophagy of Glioma Cells by Targeting Mir-383 and Regulating PRDX-3 Expression.

LRIG3 Suppresses Angiogenesis by Regulating the PI3K/AKT/VEGFA Signaling Pathway in Glioma

Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity

[LRIG3 Gene Regulates Biological Activity of GL15 Cell Line].

The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma

LRIG1 Improves Chemosensitivity Through Inhibition of BCL-2 and MnSOD in Glioblastoma

The Long Non-Coding RNA SNHG1 Promotes Glioma Progression by Competitively Binding to Mir-194 to Regulate PHLDA1 Expression

LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway.

LRRC4 Inhibits Human Glioblastoma Cells Proliferation, Invasion, and Prommp‐2 Activation by Reducing SDF‐1α/CXCR4‐mediated ERK1/2 and Akt Signaling Pathways